Correspondence 0001558370-23-016026 from Ampio Pharmaceuticals, Inc. (AMPE) (CIK 0001411906)
Ampio Pharmaceuticals, Inc. (AMPE) (CIK 0001411906)
Date: Sept. 26, 2023 · CIK: 0001411906 · Accession: 0001558370-23-016026
AI Filing Summary & Sentiment
File numbers found in text: 333-274558
Letter
Ampio Pharmaceuticals, Inc.
9800 Mount Pyramid Court, Suite 400
Englewood, Colorado 80112
September 26, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tyler Howes
Re:Ampio Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-274558
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Ampio Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests acceleration of the effective date of the above-referenced Registration Statement so that the same shall become effective as of 4:00 p.m. Eastern Time on Wednesday, September 27, 2023, or as soon as practicable thereafter or at such later time as the Company may orally request via telephone call to the staff of the Commission. The Company hereby authorizes April Hamlin of Ballard Spahr LLP, counsel to the Company, to make such request on its behalf.
If you have any questions regarding this request, please contact Ms. Hamlin at (612) 371-3522. In addition, once the Registration Statement has been declared effective, please orally confirm that event with Ms. Hamlin.
Very truly yours,
Show Raw Text
CORRESP 1 filename1.htm Ampio Pharmaceuticals, Inc. 9800 Mount Pyramid Court, Suite 400 Englewood, Colorado 80112 September 26, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re:Ampio Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-274558 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Ampio Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests acceleration of the effective date of the above-referenced Registration Statement so that the same shall become effective as of 4:00 p.m. Eastern Time on Wednesday, September 27, 2023, or as soon as practicable thereafter or at such later time as the Company may orally request via telephone call to the staff of the Commission. The Company hereby authorizes April Hamlin of Ballard Spahr LLP, counsel to the Company, to make such request on its behalf. If you have any questions regarding this request, please contact Ms. Hamlin at (612) 371-3522. In addition, once the Registration Statement has been declared effective, please orally confirm that event with Ms. Hamlin. Very truly yours, AMPIO PHARMACEUTICALS, INC. /s/ Daniel Stokely Name: Daniel Stokely Title: Chief Financial Officer